Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.

An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.

Rask C, Lund L, Lund G, Heydenreich B, Wurtzen P, Bellinghausen I, Saloga J, Lund K.

Clin Exp Allergy. 2012 Sep;42(9):1356-68. doi: 10.1111/j.1365-2222.2012.04026.x.

PMID:
22925322
2.

Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.

Gadermaier E, Staikuniene J, Scheiblhofer S, Thalhamer J, Kundi M, Westritschnig K, Swoboda I, Flicker S, Valenta R.

Allergy. 2011 Sep;66(9):1174-82. doi: 10.1111/j.1398-9995.2011.02592.x. Epub 2011 Apr 11.

3.

Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.

Schmid JM, Würtzen PA, Dahl R, Hoffmann HJ.

J Allergy Clin Immunol. 2016 Feb;137(2):562-70. doi: 10.1016/j.jaci.2015.05.023. Epub 2015 Jun 30.

PMID:
26141262
5.
6.

Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio.

Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L, Wüstenberg E.

Allergy. 2012 May;67(5):630-7. doi: 10.1111/j.1398-9995.2012.02801.x. Epub 2012 Mar 3.

7.
8.

Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.

Klimek L, Schendzielorz P, Pinol R, Pfaar O.

Clin Exp Allergy. 2012 Jun;42(6):936-45. doi: 10.1111/j.1365-2222.2012.03971.x.

PMID:
22909165
9.

Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.

Gadermaier E, Flicker S, Aberer W, Egger C, Reider N, Focke M, Vrtala S, Kundi M, Valenta R.

Int Arch Allergy Immunol. 2010;151(1):17-27. doi: 10.1159/000232567. Epub 2009 Aug 6.

PMID:
19672093
10.
11.

Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.

Ball T, Linhart B, Sonneck K, Blatt K, Herrmann H, Valent P, Stoecklinger A, Lupinek C, Thalhamer J, Fedorov AA, Almo SC, Valenta R.

Allergy. 2009 Apr;64(4):569-80. doi: 10.1111/j.1398-9995.2008.01910.x. Epub 2009 Feb 19.

12.

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Zieglmayer P, Focke-Tejkl M, Schmutz R, Lemell P, Zieglmayer R, Weber M, Kiss R, Blatt K, Valent P, Stolz F, Huber H, Neubauer A, Knoll A, Horak F, Henning R, Valenta R.

EBioMedicine. 2016 Sep;11:43-57. doi: 10.1016/j.ebiom.2016.08.022. Epub 2016 Aug 20.

13.

Immunotherapy with a Phleum pratense allergen extract induces an immune response to a grass-mix allergen extract.

Martínez-Cócera C, Sastre J, Cimarra M, Quirce S, Fernández-Rivas M, Enríquez-Matas A, Rodríguez-Alvarez M, Martín S.

J Investig Allergol Clin Immunol. 2010;20(1):13-9.

14.

Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.

TePas EC, Hoyte EG, McIntire JJ, Umetsu DT.

Ann Allergy Asthma Immunol. 2004 Jan;92(1):25-31.

PMID:
14756461
15.

Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy.

Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, Kraft D, Valenta R.

Eur J Immunol. 1999 Jun;29(6):2026-36.

16.

Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen.

Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O.

Clin Exp Allergy. 1997 Sep;27(9):1007-15.

PMID:
9678832
17.

Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores.

Hessenberger M, Weiss R, Weinberger EE, Boehler C, Thalhamer J, Scheiblhofer S.

Vaccine. 2013 Jul 25;31(34):3427-34. doi: 10.1016/j.vaccine.2012.09.086. Epub 2012 Dec 27.

18.

Phleum pratense alone is sufficient for allergen-specific immunotherapy against allergy to Pooideae grass pollens.

Hejl C, Wurtzen PA, Kleine-Tebbe J, Johansen N, Broge L, Ipsen H.

Clin Exp Allergy. 2009 May;39(5):752-9. doi: 10.1111/j.1365-2222.2008.03195.x. Epub 2009 Feb 16.

PMID:
19222498
19.

Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy.

Henmar H, Lund G, Lund L, Petersen A, Würtzen PA.

Clin Exp Immunol. 2008 Sep;153(3):316-23. doi: 10.1111/j.1365-2249.2008.03710.x. Epub 2008 Jul 18.

20.

Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity.

Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR.

J Immunol. 2004 Mar 1;172(5):3252-9.

Supplemental Content

Support Center